The loan and the $192 million cash left at the end of 2017 will support a Heplisav-B sales team and the clinical trials of SD-101.

Vaccine protection against H3N2 viruses—the predominant strain that tends to cause more severe illness—was only 25% this year.

While only in the very early stages of its important Shingrix launch, GlaxoSmithKline turned in enough vaccine sales to lead the industry in 2017.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.

Sanofi's vaccine outfit grew revenues 8.3% in 2017 to €5.1 billion ($6.25 billion), chipping in growth as the company's pharma segment struggled.

Here is some other vaccine news of note for the week.

With a second set of phase 3 data in hand for smallpox vaccine Imvamune, Bavarian Nordic is gearing up for a U.S. filing later this year.

Despite new challenges in shingles, Merck's vaccine business kept churning in 2017, generating sales of $6.5 billion—an increase of 4.8%.